RICHMOND, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) will be a presenter at the Fourth Annual OneMedForumBusiness Development and Finance Conference. The Conference will take place in San Francisco on Jan. 11-13, 2011, at the Sir Francis Drake Hotel. BioCurex Executive Chairman Denis Burger is scheduled to present on behalf of the Company on Tuesday, January 11, 2011 at 2:45 p.m. PST in the Renaissance Room, Mezzanine Level.
The Forum will bring together some of the most promising emerging medical technology and life science companies with strategic and financial investors specializing in these areas.
Focused panel sessions help CEOs connect with financial and strategic investors involved in specific sectors and will include focused networking and breakout sessions.
Panels will include top business development executives and leading investors who will discuss the "drivers and disrupters" facing their sector. Delegates will gain insight into the types of companies and technologies in which these market leaders are investing.
The focus of the OneMedForum Conference has been on the discovery of the most promising private and emerging public companies. Over 120 companies will present.
A webcast of the BioCurex, Inc. presentation will be available live on Ustream channel:
.
"We are looking forward to this opportunity to present at the OneMedForum Business Development and Finance Conference," said Burger. "We plan to educate key industry professionals about our RECAF™ cancer marker and showcase how we believe our technology can advance cancer detection and treatment in both humans and companion animals."
For more information on the Conference, visit .
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF™.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Inverness Medical Innovations. For further information on these agreements visit:
.
For more information about the Company, please visit .
For more information about OncoPet Diagnostics Inc., please visit: .
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.
CONTACT: Company Contact: Antonia Haughton BioCurex, Inc. 604-207-9150 www.BioCurex.com Investor Relations Contact: Tony Schor or James Foy Investor Awareness, Inc. 847-945-2222 www.InvestorAwareness.com